Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

518P - Identification and characterization of neuroblastoma prognostic subtypes based on programmed cell death signatures

Date

07 Dec 2024

Session

Poster Display session

Presenters

Ye Hong

Citation

Annals of Oncology (2024) 35 (suppl_4): S1580-S1594. 10.1016/annonc/annonc1694

Authors

Y. Hong

Author affiliations

  • Radiation Oncology Center, Affiliated Cancer Hospital of Chongqing University, 400000 - Chongqing/CN

Resources

This content is available to ESMO members and event participants.

Abstract 518P

Background

Different levels of evidences have demonstrated programmed cell death (PCD) were significantly associated with the development, prognosis and tumor microenvironment (TME) of cancer. No studies have explored the PCD patterns for neuroblastoma.

Methods

Here, we collected neuroblastoma transcriptome and clinical data from public databases and performed integrated analysis to dissect the PCD patterns and their roles in prognosis, clinical and molecular characteristics and TME.

Results

We identified three neuroblastoma subtypes with different PCD patterns: cluster 1 characterized by highest ferroptosis score, necroptosis score and pyroptosis score, cluster 2 with best survival characterized by highest autophagy score, and cluster 3 with worst survival characterized by highest apoptosis score. The clinical and molecular characteristic of three PCD subtypes were consistent with clinical knowledge. The sensitivity of three PCD subtypes to chemotherapeutic drugs was opposite to survival results, which might be attributed to the difference in neuroblastoma differentiation. Analyses of TME indicated cluster 1 had an immune-hot TME and cluster 3 had an immune-cold TME. The distribution of MYCN expression was lowest in cluster1 and highest in cluster 3 which was completely opposite to TME and score of known immunogenic cell death including necroptosis and pyroptosis. We speculated MYCN might regulate immunogenic cell death and cancer immunity to affect the development and prognosis of neuroblastoma.

Conclusions

The correlation among MYCN, immunogenic cell death and TME could provide a novel insight to immune checkpoint inhibitor monotherapy or combination of immunogenic cell death induced drugs and immune therapy, to potentiate the efficacy and improve the prognosis of neuroblastoma with a certain PCD patterns.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.